Triple SupremeZen Plus 3500, packaged in cardboard blisters containing one capsule per card, Distributed by Yolo Studio, Cliffside Park, NJ
Published May 26, 2021 · Recall initiated: April 6, 2021
Summary
FDA records drug Class II recall D-0383-2021, published May 26, 2021 and initiated April 6, 2021. Recalling firm: Hyobin LLC; Status: Ongoing; Reported quantity: 300 cards; Lot: all lots. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil.
What to do
Voluntary: Firm initiated · Press Release
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Hyobin LLC
- Distributor
- USA Nationwide
- Lot
- all lots
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAPremierZen Black 5000, packaged in cardboard blisters containing one capsule per card, Distributed by YoloMay 26, 2021
- FDASterile Water for Inj., USP, 25 x 100 mL Single Dose Vials per carton, Rx only, For Drug Diluent Use Only,May 26, 2021
- FDAAsenapine Sublingual Tablets, 5 mg, Rx Only, 60 Tablets, Sigmapharm Laboratories, LLC, Bensalem, PA, 19020 NDCMay 26, 2021
- FDAPreferred Pharmaceuticals Inc., Metformin HCl, Extended Release Tab. USP 500 mg, Generic for Glucophage XR, RxMay 26, 2021
- FDAHaloperidol Decanoate Injection, USP 100 mg/mL, 1 mL Single Dose Vials, Rx Only, Sterile, 10 Vials, TevaMay 26, 2021
- FDAHydrocodone Bitartrate and Homatropine Methlybromide tablets, USP, 5 mg/ 1.5 mg, 30-count bottle, Rx only,May 26, 2021
Questions about this recall
Was Triple SupremeZen Plus 3500, packaged in cardboard blisters containing one capsule per card, Distributed by Yolo Studio, Cliffside Park, NJ recalled?
Yes. FDA published recall D-0383-2021 on May 26, 2021. Reported hazard: Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil.
What should I do if I have this product?
Voluntary: Firm initiated · Press Release